Search

Your search keyword '"Bardi, E."' showing total 132 results
Start Over Author "Bardi, E."
132 results on '"Bardi, E."'

2. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Author

Salluzzi, Marina, Blenkin, Nicole, Dueck, Ashley, Doram, Craig, Zhang, Qiao, Kenney, Carol, Ryckborst, Karla, Bohn, Shelly, Collier, Quentin, Taylor, Frances, Lethebe, B. Cord, Jambula, Anitha, Sage, Kayla, Toussaint, Lana, Save, Supryia, Lee, Jaclyn, Laham, N, Sultan, A.A., Deepak, A., Sitaram, A., Demchuk, Andrew M., Lockey, A., Micielli, A., Wadhwa, A., Arabambi, B., Graham, B., Bogiatzi, Chrysi, Doshi, Darshan, Chakraborty, D., Kim, Diana, Vasquez, D, Singh, D, Tse, Dominic, Harrison, E., Smith, E.E., Teleg, E., Klourfeld, E., Klein, G., Sebastian, I.A., Evans, J, Hegedus, J, Kromm, J, Lin, K, Ignacio, K, Ghavami, Kimia, Ismail, M., Moores, M., Panzini, M.A., Boyko, M., Almekhlafi, M.A., Newcommon, Nancy, Maraj, N., Imoukhuede, O., Volny, O., Stys, Peter, Couillard, Phillipe, Ojha, P., Eswaradass, P., Joundi, Raed, Singh, R., Asuncion, R.M., Muir, R.T., Dey, S., Mansoor, S., Wasyliw, S., Nagendra, S., Hu, Sherry, Althubait, S., Chen, S., Bal, S., Van Gaal, Stephen, Peters, Steven, Ray, Sucharita, Chaturvedi, S., Subramaniam, Suresh, Fu, Vivian, Villaluna, K., Maclean, G., King-Azote, P., Ma, C., Plecash, A., Murphy, C., Gorman, J., Wilson, L., Zhou, L., Benevente, O., Teal, P., Yip, S., Mann, S., Dewar, B., Demetroff, M., Shamloul, R., Beardshaw, R., Roberts, S., Blaquiere, D., Stotts, G., Shamy, M., Bereznyakova, O., Fahed, R., Alesefir, W., Lavoie, Suzy, Hache, A., Collard, K, Mackey, A., Gosselin-Lefebvre, S., Verreault, S., Beauchamp, B., Lambourn, L., Khaw, A., Mai, L., Sposato, L., Bres Bullrich, M., Azarpazhooh, R., Fridman, S., Kapoor, A., Southwell, A., Bardi, E., Fatakdawala, I., Kamra, M, Lopes, K., Popel, N., Norouzi, V., Liu, A., Liddy, A.M., Ghoari, B., Hawkes, C., Enriquez, C.A., Gladstone, D.J., Manosalva Alzate, H.A., Khosravani, H., Hopyan, J.J., Sivakumar, K., Son, M., Boulos, M.I., Hamind, M.A., Swartz, R.H., Murphy, R., Reiter, S., Fitzpatrick, T., Bhandari, V., Good, J., Penn, M., Naylor, M., Frost, S., Cayley, A., Akthar, F., Williams, J., Kalman, L., Crellin, L., Wiegner, R., Singh, R.S., Stewart, T., To, W., Singh, S., Pikula, A., Jaigobin, C., Carpani, F., Silver, F., Janssen, H., Schaafsma, J., del Campo, M., Alskaini, M., Rajendram, P., Fairall, P., Granfield, B., Crawford, D., Jabs, J., White, L., Sivakumar, L., Piquette, L., Nguyen, T., Nomani, A., Wagner, A., Alrohimi, A., Butt, A., D'Souza, A., Gajurel, B., Vekhande, C., Kamble, H., Kalashyan, H., Lloret, M., Benguzzi, M., Arsalan, N., Ishaque, N., Ashayeriahmadabad, R., Samiento, R., Hosseini, S., Kazi, S., Das, S., Sugumar, T., Selchen, D., Kostyrko, P., Muccilli, A., Saposnik, A.G., Vandervelde, C., Ratnayake, K., McMillan, S., Katsanos, A., Shoamanesh, A., Sahlas, D.J., Naidoo, V., Todorov, V., Toma, H., Brar, J., Lee, J., Horton, M., Shand, E., Weatherby, S., Jin, A., Durafourt, B., Jalini, S., Gardner, A., Tyson, C., Junk, E., Foster, K., Bolt, K., Sylvain, N., Maley, S., Urroz, L., Peeling, L., Kelly, M., Whelan, R., Cooley, R., Teitelbaum, J., Boutayeb, A., Moore, A., Cole, E., Waxman, L., Ben-Amor, N., Sanchez, R., Khalil, S., Nehme, A., Legault, C., Tampieri, D., Ehrensperger, E., Vieira, L., Cortes, M., Angle, M., Hannouche, M., Badawy, M., Werner, K., Wieszmuellner, S., Langer, A., Gisold, A., Zach, H., Rommer, P., Macher, S., Blechinger, S., Marik, W., Series, W., Baumgartinger, M., Krebs, S., Koski, J., Eirola, S., Ivanoff, T., Erakanto, A., Kupari, L., Sibolt, G., Panula, J., Tomppo, L., Tiainen, M., Ahlstrom, M., Martinez Majander, N., Suomalainen, O., Raty, S., Levi, C., Kerr, E., Allen, J., Kaauwai, L.P., Belevski, L., Russell, M., Ormond, S., Chew, A., Loiselle, A., Royan, A., Hughes, B., Garcia Esperon, C., Pepper, E., Miteff, F., He, J., Lycett, M., Min, M., Murray, N., Pavey, N., Starling de Barros, R., Gangadharan, S., Dunkerton, S., Waller, S., Canento Sanchez, T., Wellings, T., Edmonds, G., Whittaker, K.A., Ewing, M., Lee, P., Singkang, R., McDonald, A., Dos Santos, A., Shin, C., Jackson, D., Tsoleridis, J., Fisicchia, L., Parsons, N., Shenoy, N., Smith, S., Sharobeam, A., Balabanski, A., Park, A., Williams, C., Pavlin-Premri, D., Rodrigues, E., Alemseged, F., Ng, F., Zhao, H., Beharry, J., Ng, J.L., Williamson, J., Wong, J.Z.W., Li, K., Kwan, M.K., Valente, M., Yassi, N., Yogendrakumar, V., McNamara, B., Buchanan, C., McCarthy, C., Thomas, G., Stephens, K., Chung, M., Chung, M.F., Tang, M., Busch, T., Frost, T., Lee, R., Stuart, N., Pachani, N., Menon, A., Borojevic, B., Linton, C.M., Garcia, G., Callaly, E.P., Dewey, H., Liu, J., Chen, J., Wong, J., Nowak, K., To, K., Lizak, N.S., Bhalala, O., Park, P., Tan, P., Martins, R., Cody, R., Forbes, R., Chen, S.K., Ooi, S., Tu, S., Dang, Y.L., Ling, Z., Cranefield, J., Drew, R., Tan, A., Kurunawai, C., Harvey, J., Mahadevan, J.J., Cagi, L., Palanikumar, L., Chia, L.N., Goh, R., El-Masri, S., Urbi, B., Rapier, C., Berrill, H., McEvoy, H., Dunning, R., Kuriakose, S., Chad, T., Sapaen, V., Sabet, A., Shah, D., Yeow, D., Lilley, K., Ward, K., Mozhy Mahizhnan, M., Tan, M., Lynch, C., Coveney, S., Tobin, K., McCabe, J., Marnane, M., Murphy, S., Large, M., Moynihan, B., Boyle, K., Sanjuan, E., Sanchis, M., Boned, S., Pancorbo, O., Sala, V., Garcia, L., Garcia-Tornel, A., Juega, J., Pagola, J., Santana, K., Requena, M., Muchada, M., Olive, M., Lozano, P.J., Rubiera, M., Deck, M., Rodriguez, N., Gomez, B., Reyes Munoz, F.J., Gomez, A.S., Sanz, A.C., Garcia, E.C., Penacoba, G., Ramos, M.E., de Lera Alfonso, M., Feliu, A, Pardo, L., Ramirez, P., Murillo, A., Lopez Dominguez, D., Rodriguez, J., Terceno Izaga, M., Reina, M., Viturro, S.B., Bojaryn, U., Vera Monge, V.A., Silva Blas, Y., R Siew, R., Agustin, S J, Seet, C., Tianming, T., d'Emden, A., Murray, A., Welch, A., Hatherley, K., Day, N., Smith, W., MacRae, E., Mitchell, E.S., Mahmood, A., Elliot, J., Neilson, S., Biswas, V., Brown, C., Lewis, A., Ashton, A., Werring, D., Perry, R., Muhammad, R., Lee, Y.C., Black, A., Robinson, A., Williams, A., Banaras, A., Cahoy, C., Raingold, G., Marinescu, M., Atang, N., Bason, N., Francia, N., Obarey, S., Feerick, S., Joseph, J., Schulz, U., Irons, R., Benjamin, J., Quinn, L., Jhoots, M., Teal, R., Ford, G., Harston, G., Bains, H., Gbinigie, I., Mathieson, P., Sim, C.H., Hayter, E., Kennedy, K., Binnie, L., Priestley, N., Williams, R., Ghatala, R., Stratton, S., Blight, A., Zhang, L., Davies, A., Duffy, H., Roberts, J., Homer, J., Roberts, K., Dodd, K., Cawley, K., Martin, M., Leason, S., Cotgreave, S., Taylor, T., Nallasivan, A., Haider, S., Chakraborty, T., Webster, T., Gil, A., Martin, B., Joseph, B., Cabrera, C., Jose, D., Man, J., Aquino, J., Sebastian, S., Osterdahl, M., Kwan, M., Matthew, M., Ike, N., Bello, P., Wilding, P., Fuentes, R., Shah, R., Mashate, S., Patel, T., Nwanguma, U., Dave, V., Haber, A., Lee, A., O'Sullivan, A., Drumm, B., Dawson, A.C., Matar, T., Roberts, D., Taylor, E., Rounis, E., El-Masry, A., O'Hare, C., Kalladka, D., Jamil, S., Auger, S., Raha, O., Evans, M., Vonberg, F., Kalam, S., Ali Sheikh, A., Jenkins, I.H., George, J., Kwan, J., Blagojevic, J., Saeed, M., Haji-Coll, M., Tsuda, M., Sayed, M., Winterkron, N., Thanbirajah, N., Vittay, O., Karim, R., Smail, R.C., Gauhar, S., Elmamoun, S., Malani, S., Pralhad Kelavkar, S., Hiden, J., Ferdinand, P., Sanyal, R., Varquez, R., Smith, B., Okechukwu, C., Fox, E., Collins, E., Courtney, K., Tauro, S., Patterson, C., McShane, D., Roberts, G., McIImoyle, J., McGuire, K., Fearon, P., Gordon, P., Isaacs, K., Lucas, K., Smith, L., Dews, L., Bates, M., Lawrence, S., Heeley, S., Patel, V., Chin, Y.M., Sims, D., Littleton, E., Khaira, J., Nadar, K., Kieliszkowska, A., Sari, B., Domingos Belo, C., Smith, E., Manolo, E.Y., Aeron-Thomas, J., Doheny, M., Garcia Pardo, M., Recaman, M., Tibajia, M.C., Aissa, M., Mah, Y., Yu, T., Meenakshisundaram, S., Heller, S., Alsukhni, R., Williams, O., Farag, M., Benger, M., Engineer, A., Bayhonan, S., Conway, S., Bhalla, A., Nouvakis, D., Theochari, E., Boyle, F., Teo, J., King-Robson, J., Law, K.Y., Sztriha, L., McGovern, A., Day, D., Mitchell-Douglas, J., Francis, J., Iqbal, A., Punjabivaryani, P., Anonuevo Reyes, J., Anonuevo Reyes, M., Pauls, M., Buch, A., Hedstrom, A., Hutchinson, C., Kirkland, C., Newham, J., Wilkes, G., Fleming, L., Fleck, N., Franca, A., Chwal, B., Oldoni, C., Mantovani, G., Noll, G., Zanella, L., Soma, M., Secchi, T., Borelli, W., Rimoli, B.P., da Cunha Silva, G.H., Machado Galvao Mondin, L.A., Barbosa Cerantola, R., Imthon, A.K., Esaki, A.S., Camilo, M., Vincenzi, O.C., ds Cruz, R.R., Morillos, M.B., Riccioppa Rodrigues, G.G., Santos Ferreira, K., Pazini, A.M., Pena Pereira, M.A., de Albuquerque, A.L.A., Massote Fontanini, C.E., Matinez Rubio, C.F., dos Santos, D.T., Dias, F.A., Alves, F.F.A., Milani, C., Pegorer Santos, B., Winckler, F., De Souza, J.T., Bonome, L.A.M., Cury Silva, V.A., Teodoro, R.S., Modolo, G.P., Ferreira, N.C., Barbosa dos Santos, D.F., dos Santos Moreira, J.C., Cruz Guedes de Morais, A.B., Vieira, J., Mendes, G., de Queiroz, J.P., Coutts, Shelagh B, Ankolekar, Sandeep, Appireddy, Ramana, Arenillas, Juan F, Assis, Zarina, Bailey, Peter, Barber, Philip A, Bazan, Rodrigo, Buck, Brian H, Butcher, Ken S, Camden, Marie-Christine, Campbell, Bruce C V, Casaubon, Leanne K, Catanese, Luciana, Chatterjee, Kausik, Choi, Philip M C, Clarke, Brian, Dowlatshahi, Dar, Ferrari, Julia, Field, Thalia S, Ganesh, Aravind, Ghia, Darshan, Goyal, Mayank, Greisenegger, Stefan, Halse, Omid, Horn, Mackenzie, Hunter, Gary, Imoukhuede, Oje, Kelly, Peter J, Kennedy, James, Kleinig, Timothy J, Krishnan, Kailash, Lima, Fabricio, Mandzia, Jennifer L, Marko, Martha, Martins, Sheila O, Medvedev, George, Menon, Bijoy K, Mishra, Sachin M, Molina, Carlos, Moussaddy, Aimen, Muir, Keith W, Parsons, Mark W, Penn, Andrew M W, Pille, Arthur, Pontes-Neto, Octávio M, Roffe, Christine, Serena, Joaquin, Simister, Robert, Singh, Nishita, Spratt, Neil, Strbian, Daniel, Tham, Carol H, Wiggam, M Ivan, Williams, David J, Willmot, Mark R, Wu, Teddy, Yu, Amy Y X, Zachariah, George, Zafar, Atif, Zerna, Charlotte, and Hill, Michael D

Published
2024
Full Text
View/download PDF

3. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium

Author

Clement, S.C., Kremer, L.C.M., Verburg, F.A., Simmons, J.H., Goldfarb, M., Peeters, R.P., Alexander, E.K., Bardi, E., Brignardello, E., Constine, L.S., Dinauer, C.A., Drozd, V.M., Felicetti, F., Frey, E., Heinzel, A., van den Heuvel-Eibrink, M.M., Huang, S.A., Links, T.P., Lorenz, K., Mulder, R.L., Neggers, S.J., Nieveen van Dijkum, E.J.M., Oeffinger, K.C., van Rijn, R.R., Rivkees, S.A., Ronckers, C.M., Schneider, A.B., Skinner, R., Wasserman, J.D., Wynn, T., Hudson, M.M., Nathan, P.C., and van Santen, H.M.

Published
2018
Full Text
View/download PDF

4. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Author

Coutts, Shelagh B, Ankolekar, Sandeep, Appireddy, Ramana, Arenillas, Juan F, Assis, Zarina, Bailey, Peter, Barber, Philip A, Bazan, Rodrigo, Buck, Brian H, Butcher, Ken S, Camden, Marie-Christine, Campbell, Bruce C V, Casaubon, Leanne K, Catanese, Luciana, Chatterjee, Kausik, Choi, Philip M C, Clarke, Brian, Dowlatshahi, Dar, Ferrari, Julia, Field, Thalia S, Ganesh, Aravind, Ghia, Darshan, Goyal, Mayank, Greisenegger, Stefan, Halse, Omid, Horn, Mackenzie, Hunter, Gary, Imoukhuede, Oje, Kelly, Peter J, Kennedy, James, Kenney, Carol, Kleinig, Timothy J, Krishnan, Kailash, Lima, Fabricio, Mandzia, Jennifer L, Marko, Martha, Martins, Sheila O, Medvedev, George, Menon, Bijoy K, Mishra, Sachin M, Molina, Carlos, Moussaddy, Aimen, Muir, Keith W, Parsons, Mark W, Penn, Andrew M W, Pille, Arthur, Pontes-Neto, Octávio M, Roffe, Christine, Serena, Joaquin, Simister, Robert, Singh, Nishita, Spratt, Neil, Strbian, Daniel, Tham, Carol H, Wiggam, M Ivan, Williams, David J, Willmot, Mark R, Wu, Teddy, Yu, Amy Y X, Zachariah, George, Zafar, Atif, Zerna, Charlotte, Hill, Michael D, Salluzzi, Marina, Blenkin, Nicole, Dueck, Ashley, Doram, Craig, Zhang, Qiao, Kenney, Carol, Ryckborst, Karla, Bohn, Shelly, Collier, Quentin, Taylor, Frances, Lethebe, B. Cord, Jambula, Anitha, Sage, Kayla, Toussaint, Lana, Save, Supryia, Lee, Jaclyn, Laham, N, Sultan, A.A., Deepak, A., Sitaram, A., Demchuk, Andrew M., Lockey, A., Micielli, A., Wadhwa, A., Arabambi, B., Graham, B., Bogiatzi, Chrysi, Doshi, Darshan, Chakraborty, D., Kim, Diana, Vasquez, D, Singh, D, Tse, Dominic, Harrison, E., Smith, E.E., Teleg, E., Klourfeld, E., Klein, G., Sebastian, I.A., Evans, J, Hegedus, J, Kromm, J, Lin, K, Ignacio, K, Ghavami, Kimia, Ismail, M., Moores, M., Panzini, M.A., Boyko, M., Almekhlafi, M.A., Newcommon, Nancy, Maraj, N., Imoukhuede, O., Volny, O., Stys, Peter, Couillard, Phillipe, Ojha, P., Eswaradass, P., Joundi, Raed, Singh, R., Asuncion, R.M., Muir, R.T., Dey, S., Mansoor, S., Wasyliw, S., Nagendra, S., Hu, Sherry, Althubait, S., Chen, S., Bal, S., Van Gaal, Stephen, Peters, Steven, Ray, Sucharita, Chaturvedi, S., Subramaniam, Suresh, Fu, Vivian, Villaluna, K., Maclean, G., King-Azote, P., Ma, C., Plecash, A., Murphy, C., Gorman, J., Wilson, L., Zhou, L., Benevente, O., Teal, P., Yip, S., Mann, S., Dewar, B., Demetroff, M., Shamloul, R., Beardshaw, R., Roberts, S., Blaquiere, D., Stotts, G., Shamy, M., Bereznyakova, O., Fahed, R., Alesefir, W., Lavoie, Suzy, Hache, A., Collard, K, Mackey, A., Gosselin-Lefebvre, S., Verreault, S., Beauchamp, B., Lambourn, L., Khaw, A., Mai, L., Sposato, L., Bres Bullrich, M., Azarpazhooh, R., Fridman, S., Kapoor, A., Southwell, A., Bardi, E., Fatakdawala, I., Kamra, M, Lopes, K., Popel, N., Norouzi, V., Liu, A., Liddy, A.M., Ghoari, B., Hawkes, C., Enriquez, C.A., Gladstone, D.J., Manosalva Alzate, H.A., Khosravani, H., Hopyan, J.J., Sivakumar, K., Son, M., Boulos, M.I., Hamind, M.A., Swartz, R.H., Murphy, R., Reiter, S., Fitzpatrick, T., Bhandari, V., Good, J., Penn, M., Naylor, M., Frost, S., Cayley, A., Akthar, F., Williams, J., Kalman, L., Crellin, L., Wiegner, R., Singh, R.S., Stewart, T., To, W., Singh, S., Pikula, A., Jaigobin, C., Carpani, F., Silver, F., Janssen, H., Schaafsma, J., del Campo, M., Alskaini, M., Rajendram, P., Fairall, P., Granfield, B., Crawford, D., Jabs, J., White, L., Sivakumar, L., Piquette, L., Nguyen, T., Nomani, A., Wagner, A., Alrohimi, A., Butt, A., D'Souza, A., Gajurel, B., Vekhande, C., Kamble, H., Kalashyan, H., Lloret, M., Benguzzi, M., Arsalan, N., Ishaque, N., Ashayeriahmadabad, R., Samiento, R., Hosseini, S., Kazi, S., Das, S., Sugumar, T., Selchen, D., Kostyrko, P., Muccilli, A., Saposnik, A.G., Vandervelde, C., Ratnayake, K., McMillan, S., Katsanos, A., Shoamanesh, A., Sahlas, D.J., Naidoo, V., Todorov, V., Toma, H., Brar, J., Lee, J., Horton, M., Chen, S., Shand, E., Weatherby, S., Jin, A., Durafourt, B., Jalini, S., Gardner, A., Tyson, C., Junk, E., Foster, K., Bolt, K., Sylvain, N., Maley, S., Urroz, L., Peeling, L., Kelly, M., Whelan, R., Cooley, R., Teitelbaum, J., Boutayeb, A., Moore, A., Cole, E., Waxman, L., Ben-Amor, N., Sanchez, R., Khalil, S., Nehme, A., Legault, C., Tampieri, D., Ehrensperger, E., Vieira, L., Cortes, M., Angle, M., Hannouche, M., Badawy, M., Werner, K., Wieszmuellner, S., Langer, A., Gisold, A., Zach, H., Rommer, P., Macher, S., Blechinger, S., Marik, W., Series, W., Baumgartinger, M., Krebs, S., Koski, J., Eirola, S., Ivanoff, T., Erakanto, A., Kupari, L., Sibolt, G., Panula, J., Tomppo, L., Tiainen, M., Ahlstrom, M., Martinez Majander, N., Suomalainen, O., Raty, S., Levi, C., Kerr, E., Allen, J., Kaauwai, L.P., Belevski, L., Russell, M., Ormond, S., Chew, A., Loiselle, A., Royan, A., Hughes, B., Garcia Esperon, C., Pepper, E., Miteff, F., He, J., Lycett, M., Min, M., Murray, N., Pavey, N., Starling de Barros, R., Gangadharan, S., Dunkerton, S., Waller, S., Canento Sanchez, T., Wellings, T., Edmonds, G., Whittaker, K.A., Ewing, M., Lee, P., Singkang, R., McDonald, A., Dos Santos, A., Shin, C., Jackson, D., Tsoleridis, J., Fisicchia, L., Parsons, N., Shenoy, N., Smith, S., Sharobeam, A., Balabanski, A., Park, A., Williams, C., Pavlin-Premri, D., Rodrigues, E., Alemseged, F., Ng, F., Zhao, H., Beharry, J., Ng, J.L., Williamson, J., Wong, J.Z.W., Li, K., Kwan, M.K., Valente, M., Yassi, N., Cooley, R., Yogendrakumar, V., McNamara, B., Buchanan, C., McCarthy, C., Thomas, G., Stephens, K., Chung, M., Chung, M.F., Tang, M., Busch, T., Frost, T., Lee, R., Stuart, N., Pachani, N., Menon, A., Borojevic, B., Linton, C.M., Garcia, G., Callaly, E.P., Dewey, H., Liu, J., Chen, J., Wong, J., Nowak, K., To, K., Lizak, N.S., Bhalala, O., Park, P., Tan, P., Martins, R., Cody, R., Forbes, R., Chen, S.K., Ooi, S., Tu, S., Dang, Y.L., Ling, Z., Cranefield, J., Drew, R., Tan, A., Kurunawai, C., Harvey, J., Mahadevan, J.J., Cagi, L., Palanikumar, L., Chia, L.N., Goh, R., El-Masri, S., Urbi, B., Rapier, C., Berrill, H., McEvoy, H., Dunning, R., Kuriakose, S., Chad, T., Sapaen, V., Sabet, A., Shah, D., Yeow, D., Lilley, K., Ward, K., Mozhy Mahizhnan, M., Tan, M., Lynch, C., Coveney, S., Tobin, K., McCabe, J., Marnane, M., Murphy, S., Large, M., Moynihan, B., Boyle, K., Sanjuan, E., Sanchis, M., Boned, S., Pancorbo, O., Sala, V., Garcia, L., Garcia-Tornel, A., Juega, J., Pagola, J., Santana, K., Requena, M., Muchada, M., Olive, M., Lozano, P.J., Rubiera, M., Deck, M., Rodriguez, N., Gomez, B., Reyes Munoz, F.J., Gomez, A.S., Sanz, A.C., Garcia, E.C., Penacoba, G., Ramos, M.E., de Lera Alfonso, M., Feliu, A, Pardo, L., Ramirez, P., Murillo, A., Lopez Dominguez, D., Rodriguez, J., Terceno Izaga, M., Reina, M., Viturro, S.B., Bojaryn, U., Vera Monge, V.A., Silva Blas, Y., R Siew, R., Agustin, S J, Seet, C., Tianming, T., d'Emden, A., Murray, A., Welch, A., Hatherley, K., Day, N., Smith, W., MacRae, E., Mitchell, E.S., Mahmood, A., Elliot, J., Neilson, S., Biswas, V., Brown, C., Lewis, A., Ashton, A., Werring, D., Perry, R., Muhammad, R., Lee, Y.C., Black, A., Robinson, A., Williams, A., Banaras, A., Cahoy, C., Raingold, G., Marinescu, M., Atang, N., Bason, N., Francia, N., Obarey, S., Feerick, S., Joseph, J., Schulz, U., Irons, R., Benjamin, J., Quinn, L., Jhoots, M., Teal, R., Ford, G., Harston, G., Bains, H., Gbinigie, I., Mathieson, P., Irons, R., Sim, C.H., Hayter, E., Kennedy, K., Binnie, L., Priestley, N., Williams, R., Ghatala, R., Stratton, S., Blight, A., Zhang, L., Davies, A., Duffy, H., Roberts, J., Homer, J., Roberts, K., Dodd, K., Cawley, K., Martin, M., Leason, S., Cotgreave, S., Taylor, T., Nallasivan, A., Haider, S., Chakraborty, T., Webster, T., Gil, A., Martin, B., Joseph, B., Cabrera, C., Jose, D., Man, J., Aquino, J., Sebastian, S., Osterdahl, M., Kwan, M., Matthew, M., Ike, N., Bello, P., Wilding, P., Fuentes, R., Shah, R., Mashate, S., Patel, T., Nwanguma, U., Dave, V., Haber, A., Lee, A., O'Sullivan, A., Drumm, B., Dawson, A.C., Matar, T., Biswas, V., Roberts, D., Taylor, E., Rounis, E., El-Masry, A., O'Hare, C., Kalladka, D., Jamil, S., Auger, S., Raha, O., Evans, M., Vonberg, F., Kalam, S., Ali Sheikh, A., Jenkins, I.H., George, J., Kwan, J., Blagojevic, J., Saeed, M., Haji-Coll, M., Tsuda, M., Sayed, M., Winterkron, N., Thanbirajah, N., Vittay, O., Karim, R., Smail, R.C., Gauhar, S., Elmamoun, S., Malani, S., Pralhad Kelavkar, S., Hiden, J., Ferdinand, P., Sanyal, R., Varquez, R., Smith, B., Okechukwu, C., Fox, E., Collins, E., Courtney, K., Tauro, S., Patterson, C., McShane, D., Kerr, E., Roberts, G., McIImoyle, J., McGuire, K., Fearon, P., Gordon, P., Isaacs, K., Lucas, K., Smith, L., Dews, L., Bates, M., Lawrence, S., Heeley, S., Patel, V., Chin, Y.M., Sims, D., Littleton, E., Khaira, J., Nadar, K., Kieliszkowska, A., Sari, B., Domingos Belo, C., Smith, E., Manolo, E.Y., Aeron-Thomas, J., Doheny, M., Garcia Pardo, M., Recaman, M., Tibajia, M.C., Aissa, M., Mah, Y., Yu, T., Patel, V., Meenakshisundaram, S., Heller, S., Alsukhni, R., Williams, O., Farag, M., Benger, M., Engineer, A., Aissa, M., Bayhonan, S., Conway, S., Bhalla, A., Nouvakis, D., Theochari, E., Boyle, F., Teo, J., King-Robson, J., Law, K.Y., Sztriha, L., Ismail, M., McGovern, A., Day, D., Mitchell-Douglas, J., Francis, J., Iqbal, A., Punjabivaryani, P., Anonuevo Reyes, J., Anonuevo Reyes, M., Pauls, M., Buch, A., Hedstrom, A., Hutchinson, C., Kirkland, C., Newham, J., Wilkes, G., Fleming, L., Fleck, N., Franca, A., Chwal, B., Oldoni, C., Mantovani, G., Noll, G., Zanella, L., Soma, M., Secchi, T., Borelli, W., Rimoli, B.P., da Cunha Silva, G.H., Machado Galvao Mondin, L.A., Barbosa Cerantola, R., Imthon, A.K., Esaki, A.S., Camilo, M., Vincenzi, O.C., ds Cruz, R.R., Morillos, M.B., Riccioppa Rodrigues, G.G., Santos Ferreira, K., Pazini, A.M., Pena Pereira, M.A., de Albuquerque, A.L.A., Massote Fontanini, C.E., Matinez Rubio, C.F., dos Santos, D.T., Dias, F.A., Alves, F.F.A., Milani, C., Pegorer Santos, B., Winckler, F., De Souza, J.T., Bonome, L.A.M., Cury Silva, V.A., Teodoro, R.S., Modolo, G.P., Ferreira, N.C., Barbosa dos Santos, D.F., dos Santos Moreira, J.C., Cruz Guedes de Morais, A.B., Vieira, J., Mendes, G., and de Queiroz, J.P.

Abstract

Individuals with minor ischaemic stroke and intracranial occlusion are at increased risk of poor outcomes. Intravenous thrombolysis with tenecteplase might improve outcomes in this population. We aimed to test the superiority of intravenous tenecteplase over non-thrombolytic standard of care in patients with minor ischaemic stroke and intracranial occlusion or focal perfusion abnormality.

Published
2024
Full Text
View/download PDF

6. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study

Author

Baat, E.C. de, Feijen, Elizabeth A.M., Reulen, Raoul C., Allodji, Rodrigue S., Bagnasco, Francesca, Bardi, E., Loonen, J.J., Hawkins, M., Kremer, Leontien C.M., Baat, E.C. de, Feijen, Elizabeth A.M., Reulen, Raoul C., Allodji, Rodrigue S., Bagnasco, Francesca, Bardi, E., Loonen, J.J., Hawkins, M., and Kremer, Leontien C.M.

Abstract

Item does not contain fulltext

Published
2023

8. Upper limb soft robotic wearable devices: a systematic review

Author

Bardi, E., Gandolla, M., Braghin, F., Resta, F., Pedrocchi, A. L. G., and Ambrosini, E.

Subjects
Rehabilitation, Soft robotics, Health Informatics, Robotics, Exoskeleton Device, Exosuits, Upper Extremity, Exoskeletons, Wearable Electronic Devices, Assistive technology, Elbow, Humans, Rehabilitation robotics, Upper limb
Abstract

Introduction Soft robotic wearable devices, referred to as exosuits, can be a valid alternative to rigid exoskeletons when it comes to daily upper limb support. Indeed, their inherent flexibility improves comfort, usability, and portability while not constraining the user’s natural degrees of freedom. This review is meant to guide the reader in understanding the current approaches across all design and production steps that might be exploited when developing an upper limb robotic exosuit. Methods The literature research regarding such devices was conducted in PubMed, Scopus, and Web of Science. The investigated features are the intended scenario, type of actuation, supported degrees of freedom, low-level control, high-level control with a focus on intention detection, technology readiness level, and type of experiments conducted to evaluate the device. Results A total of 105 articles were collected, describing 69 different devices. Devices were grouped according to their actuation type. More than 80% of devices are meant either for rehabilitation, assistance, or both. The most exploited actuation types are pneumatic (52%) and DC motors with cable transmission (29%). Most devices actuate 1 (56%) or 2 (28%) degrees of freedom, and the most targeted joints are the elbow and the shoulder. Intention detection strategies are implemented in 33% of the suits and include the use of switches and buttons, IMUs, stretch and bending sensors, EMG and EEG measurements. Most devices (75%) score a technology readiness level of 4 or 5. Conclusion Although few devices can be considered ready to reach the market, exosuits show very high potential for the assistance of daily activities. Clinical trials exploiting shared evaluation metrics are needed to assess the effectiveness of upper limb exosuits on target users.

Published
2022

9. The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer

Author

Kalsbeek, R.J. van, Mulder, R.L., Haupt, R., Muraca, M., Hjorth, L., Follin, C., Kepak, T., Kepakova, K., Uyttebroeck, A., Mangelschots, M., Winther, J. Falck, Loonen, J.J., Michel, G., Bardi, E., Frederiksen, L. Elmerdahl, Hartogh, J. den, Mader, L., Roser, K., Schneider, C., Brown, M.C., Brunhofer, M., Göttgens, I.L.E., Hermens, R.P.M.G., Kienesberger, A., Korevaar, J.C., Skinner, R., Pal, H.J. van der, Kremer, L.C., Kalsbeek, R.J. van, Mulder, R.L., Haupt, R., Muraca, M., Hjorth, L., Follin, C., Kepak, T., Kepakova, K., Uyttebroeck, A., Mangelschots, M., Winther, J. Falck, Loonen, J.J., Michel, G., Bardi, E., Frederiksen, L. Elmerdahl, Hartogh, J. den, Mader, L., Roser, K., Schneider, C., Brown, M.C., Brunhofer, M., Göttgens, I.L.E., Hermens, R.P.M.G., Kienesberger, A., Korevaar, J.C., Skinner, R., Pal, H.J. van der, and Kremer, L.C.

Abstract

Item does not contain fulltext, BACKGROUND: Long-term follow-up (LTFU) care, although endorsed, is not available for the majority of adult survivors of childhood, adolescence and young adult (CAYA) cancer. Barriers to implementation include lack of time, knowledge, personnel and funding. Sustainable solutions are urgently needed to address the needs of CAYA cancer survivors to improve the quality of life and reduce the burden of late effects on survivors, health care systems and society. The European Union-funded PanCareFollowUp project, initiated by the Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer, was established to facilitate the implementation of person-centred survivorship care across Europe. PATIENTS AND METHODS: The PanCareFollowUp Care Intervention was co-developed with survivors as part of the PanCareFollowUp project. It is a person-centred approach to survivorship care, supported by guidelines and with flexibility to adapt to local health care settings. The Care Intervention consists of three steps: (1) previsit completion of a Survivor Questionnaire (by the survivor) and Treatment Summary (by the health care provider [HCP]), (2) a clinic visit including shared decision-making, and (3) a follow-up call to finalise the individualised Survivorship Care Plan. RESULTS: We developed the key components of the PanCareFollowUp Care Intervention: a PanCareFollowUp Survivor Questionnaire, Treatment Summary template, Survivorship Care Plan template, and educational materials for HCPs and survivors. Wide implementation of the PanCareFollowUp Care Intervention will be supported with a freely distributed Replication Manual on completion of the PanCareFollowUp project. CONCLUSIONS: The PanCareFollowUp Care Intervention will support the implementation of person-centred, guideline-based LTFU care in different health care settings across Europe to improve survivors' health and well-being.

Published
2022

10. Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Bone Morbidity in Children after HSCT

Author

Kuhlen, M, Kunstreich, M, Niinimaki, R, Dunstheimer, D, Lawitschka, A, Bardi, E, Willasch, A, Bader, P, Hogler, W, Peters, C, Balduzzi, A, Kuhlen M., Kunstreich M., Niinimaki R., Dunstheimer D., Lawitschka A., Bardi E., Willasch A., Bader P., Hogler W., Peters C., Balduzzi A., Kuhlen, M, Kunstreich, M, Niinimaki, R, Dunstheimer, D, Lawitschka, A, Bardi, E, Willasch, A, Bader, P, Hogler, W, Peters, C, Balduzzi, A, Kuhlen M., Kunstreich M., Niinimaki R., Dunstheimer D., Lawitschka A., Bardi E., Willasch A., Bader P., Hogler W., Peters C., and Balduzzi A.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review

Published
2020

11. Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Bone Morbidity in Children after HSCT

Author

Kuhlen M., Kunstreich M., Niinimaki R., Dunstheimer D., Lawitschka A., Bardi E., Willasch A., Bader P., Hogler W., Peters C., Balduzzi A., Kuhlen, M, Kunstreich, M, Niinimaki, R, Dunstheimer, D, Lawitschka, A, Bardi, E, Willasch, A, Bader, P, Hogler, W, Peters, C, and Balduzzi, A

Subjects
Leukemia, Allogeneic HSCT, Bone morbidity, Children and adolescent
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review

Published
2020

12. Exploiting macrofauna diadromy for assessing anthropogenic impact in American Samoa streams (1)

Author

Wade, L.M., Fanolua, F.S., Vargo, A.M., van Houte-Howes, K., Bardi, E., and Vargo, D.L.

Subjects
Water quality -- Research -- Methods, Stream fauna -- Distribution -- Influence -- Varieties -- Methods -- Research, Biological monitoring -- Methods -- Research, Stream ecology -- Research -- Methods, Rivers -- Properties -- Methods -- Research, Company distribution practices, Earth sciences, Science and technology
Abstract

Abstract: Stream biomonitoring is increasingly used to identify and monitor changes in water quality, stream habitat, and even the surrounding watershed. An effective biomonitoring protocol must comprise attributes able to [...]

Published
2008

13. European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer

Author

Kalsbeek, Rebecca J. van, Pal, Helena J.H. van der, Kremer, Leontien C.M., Bardi, E., Brown, M.C., Effeney, Rachel, Loonen, J.J., Skinner, R., Mulder, Renee L., Kalsbeek, Rebecca J. van, Pal, Helena J.H. van der, Kremer, Leontien C.M., Bardi, E., Brown, M.C., Effeney, Rachel, Loonen, J.J., Skinner, R., and Mulder, Renee L.

Abstract

Contains fulltext : 236829.pdf (Publisher’s version ) (Open Access)

Published
2021

14. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia.

Author

Andrés-Jensen, L, Attarbaschi, A, Bardi, E, Barzilai-Birenboim, S, Bhojwani, D, Hagleitner, MM, Halsey, C, Harila-Saari, A, van Litsenburg, RRL, Hudson, MM, Jeha, S, Kato, M, Kremer, L, Mlynarski, W, Möricke, A, Pieters, R, Piette, C, Raetz, E, Ronceray, L, Toro, C, Grazia Valsecchi, M, Vrooman, LM, Weinreb, S, Winick, N, Schmiegelow, K, Ponte di Legno Severe Toxicity Working Group, Andrés-Jensen, L, Attarbaschi, A, Bardi, E, Barzilai-Birenboim, S, Bhojwani, D, Hagleitner, MM, Halsey, C, Harila-Saari, A, van Litsenburg, RRL, Hudson, MM, Jeha, S, Kato, M, Kremer, L, Mlynarski, W, Möricke, A, Pieters, R, Piette, C, Raetz, E, Ronceray, L, Toro, C, Grazia Valsecchi, M, Vrooman, LM, Weinreb, S, Winick, N, Schmiegelow, K, and Ponte di Legno Severe Toxicity Working Group

Abstract

5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff fo

Published
2021

15. Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Author

Verbruggen, LC, Wang, Y, Armenian, SH, Ehrhardt, MJ, van der Pal, HJH, van Dalen, EC, van As, JW, Bardi, E, Baust, K, Berger, C, Castagnola, E, Devine, KA, Gebauer, J, Marchak, JG, Glaser, AW, Groll, AH, Haeusler, GM, den Hartogh, J, Haupt, R, Hjorth, L, Kato, M, Kepak, T, Koopman, MMWR, Langer, T, Maeda, M, Michel, G, Muraca, M, Nathan, PC, van den Oever, SR, Pavasovic, V, Sato, S, Schulte, F, Sung, L, Tissing, W, Uyttebroeck, A, Mulder, RL, Kuehni, C, Skinner, R, Hudson, MM, Kremer, LCM, Verbruggen, LC, Wang, Y, Armenian, SH, Ehrhardt, MJ, van der Pal, HJH, van Dalen, EC, van As, JW, Bardi, E, Baust, K, Berger, C, Castagnola, E, Devine, KA, Gebauer, J, Marchak, JG, Glaser, AW, Groll, AH, Haeusler, GM, den Hartogh, J, Haupt, R, Hjorth, L, Kato, M, Kepak, T, Koopman, MMWR, Langer, T, Maeda, M, Michel, G, Muraca, M, Nathan, PC, van den Oever, SR, Pavasovic, V, Sato, S, Schulte, F, Sung, L, Tissing, W, Uyttebroeck, A, Mulder, RL, Kuehni, C, Skinner, R, Hudson, MM, and Kremer, LCM

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19.

Published
2020

16. Guidance to bone morbidity in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation

Author

Kuhlen, M. (Michaela), Kunstreich, M. (Marina), Niinimäki, R. (Riitta), Dunstheimer, D. (Desiree), Lawitschka, A. (Anita), Bardi, E. (Edit), Willasch, A. (André), Bader, P. (Peter), Högler, W. (Wolfgang), Peters, C. (Christina), Balduzzi, A. (Adriana), Kuhlen, M. (Michaela), Kunstreich, M. (Marina), Niinimäki, R. (Riitta), Dunstheimer, D. (Desiree), Lawitschka, A. (Anita), Bardi, E. (Edit), Willasch, A. (André), Bader, P. (Peter), Högler, W. (Wolfgang), Peters, C. (Christina), and Balduzzi, A. (Adriana)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely performed in children and adolescents with hematologic diseases, including very high-risk leukemia. With increasing success and survival rates, the long-term sequelae of HSCT have become important. Here, we provide guidance to the prevention and treatment of the most common bone morbidities—osteoporosis and osteonecrosis—emerging in the context of HSCT in children and adolescents. We give an overview on definitions, symptoms, and diagnostics and propose an algorithm for clinical practice based on discussions within the International Berlin Frankfurt Münster (BFM) Stem Cell Transplantation Committee and the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation, our expert knowledge, and a literature review.

Published
2020

17. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Author

Clemens, Eva, Van den Heuvel - Eibrink, Marry, Mulder, RL, Kremer, LCM (Leontien), Hudson, MM, Skinner, R, Constine, LS, Bass, JK, Kuehni, CE, Langer, T, van Dalen, EC, Bardi, E, Bonne, NX, Brock, PR, Brooks, B, Carleton, B, Caron, E, Chang, KW, Johnston, K, Knight, K, Nathan, PC, Orgel, E, Prasad, PK, Rottenberg, J, Scheinemann, K, de Vries, A.C.H., Walwyn, T, Weiss, A, Zehnhoff-Dinnesen, AA, Cohn, RJ, Landier, W, Kadan-Lottick, N, Levitt, G, Hoetink, A, Mussman, J, Princess Máxima Center for Pediatric Oncology [Utrecht, Netherlands], Erasmus MC-Sophia Hospital [Rotterdam, Netherlands], Emma Children's Hospital [Amsterdam, Netherlands] (Academic Medical Center), University of Amsterdam [Amsterdam] (UvA), St Jude Children's Research Hospital, Great North Children’s Hospital [Newcastle Upon Tyne, UK], Northern Institute for Cancer Research [Newcastle] (NICR), Newcastle University [Newcastle], University of Rochester Medical Center (URMC), Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern] (UNIBE), University Hospital for Children and Adolescents [Lübeck, Germany], Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Otologie et d'Otoneurologie [CHU Lille], Centre Hospitalier Universitaire de Lille (CHU de Lille), Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK] (GOSHC), University of British Columbia (UBC), Stanford University, Sydney Children's hospital, Oregon Health and Science University [Portland] (OHSU), The Hospital for sick children [Toronto] (SickKids), Children’s Hospital Los Angeles [Los Angeles], University of Southern California (USC), Louisiana State University (LSU), Children's Hospital at New Orleans, Masaryk University [Brno] (MUNI), Kantonsspital Aarau [Aarau, Switzerland], University Hospital Basel [Basel], McMaster University [Hamilton, Ontario], Perth Children's Hospital [Nedlands, WA, Australia], The University of Western Australia (UWA), University of Regensburg, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), University of New South Wales [Sydney] (UNSW), University of Alabama at Birmingham [ Birmingham] (UAB), SALZET, Michel, Pediatrics, Universität Bern [Bern], Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK]

Subjects
Shunt placement, Pediatrics, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], Childhood cancer, Harmonization, Antineoplastic Agents, Platinum Compounds, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Ototoxicity, SDG 3 - Good Health and Well-being, Cancer Survivors, Neoplasms, otorhinolaryngologic diseases, Medicine, Humans, Young adult, 030223 otorhinolaryngology, Child, Evidence-Based Medicine, business.industry, Cancer, Guideline, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Oncology, 030220 oncology & carcinogenesis, Population Surveillance, Cranial Irradiation, business, Delivery of Health Care
Abstract

International audience; Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Published
2019
Full Text
View/download PDF

21. Late excess mortality in survivors of childhood and adolescent cancer: Results from the PanCareSurFup Study

Author

Schmidtmann, I, Byrne, J, Rashid, H, Grabow, D, Hagberg, O, Bardi, E, De Vathaire, F, Falck Winther, J, Gudmundsdottir, T, Haupt, R, Hawkins, MM, Jakab, Z, Jankovic, M, Kaatsch, P, Kremer, LMC, Kuehni, CE, Lähteenmäki, PM, Ronckers, CM, Sacerdote, C, Skinner, R, Terenziani, M, Zadravec Zaletel, L, Hjorth, L, Schmidtmann, I, Byrne, J, Rashid, H, Grabow, D, Hagberg, O, Bardi, E, De Vathaire, F, Falck Winther, J, Gudmundsdottir, T, Haupt, R, Hawkins, MM, Jakab, Z, Jankovic, M, Kaatsch, P, Kremer, LMC, Kuehni, CE, Lähteenmäki, PM, Ronckers, CM, Sacerdote, C, Skinner, R, Terenziani, M, Zadravec Zaletel, L, and Hjorth, L

Published
2019

24. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Author

Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, Hjorth, Lars, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, Jankovic, Momcilo, Haupt, Riccardo, Spinetta, John J., Beck, Joern D., Byrne, Julianne, Calaminus, Gabriele, Lackner, Herwig, Biondi, Andrea, Oeffinger, Kevin, Hudson, Melissa, Skinner, Roderick, Reaman, Gregory, van der Pal, Helena, Kremer, Leontien, Den Hartogh, Jaap, Michel, Gisela, Frey, Eva, Bardi, Edit, Hawkins, Michael, Rizvi, Katie, Terenziani, Monica, Valsecchi, Maria Grazia, Bode, Gerlind, Jenney, Meriel, de Vathaire, Florent, Garwicz, Stanislaw, Levitt, Gill A., Grabow, Desiree, Kuehni, Claudia E., Schrappe, Martin, and Hjorth, Lars

Abstract

Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).

Published
2018

25. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium

Author

Skinner, R., Mulder, R.L., Kremer, L.C., Hudson, M.M., Constine, L.S., Bardi, E., Boekhout, A., Borgmann-Staudt, A., Brown, M.C., Cohn, R., Dirksen, U., Giwercman, A., Ishiguro, H., Jahnukainen, K., Kenney, L.B., Loonen, J.J., Meacham, L., Neggers, S., Nussey, S., Petersen, C., Shnorhavorian, M., Heuvel-Eibrink, M.M. van den, Santen, H.M. van, Wallace, W.H., Green, D.M., Skinner, R., Mulder, R.L., Kremer, L.C., Hudson, M.M., Constine, L.S., Bardi, E., Boekhout, A., Borgmann-Staudt, A., Brown, M.C., Cohn, R., Dirksen, U., Giwercman, A., Ishiguro, H., Jahnukainen, K., Kenney, L.B., Loonen, J.J., Meacham, L., Neggers, S., Nussey, S., Petersen, C., Shnorhavorian, M., Heuvel-Eibrink, M.M. van den, Santen, H.M. van, Wallace, W.H., and Green, D.M.

Abstract

Item does not contain fulltext, Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired spermatogenesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and young adult cancer survivors. Guidelines for surveillance and management of potential adverse effects could improve cancer survivors' health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about optimum screening practices. This clinical practice guideline recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an international multidisciplinary panel including 25 experts in relevant medical specialties, using a consistent and transparent process. Recommendations were graded according to the strength of underlying evidence and potential benefit gained by early detection and appropriate management. The aim of the recommendations is to enhance evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, highlighting the need for further targeted research.

Published
2017

26. Transition guidelines: An important step in the future care for childhood cancer survivors: A comprehensive definition as groundwork

Author

Mulder, R, van der Pal, J, Levitt, G, Skinner, Rod, Kremer, C, Brown, C, Bardi, E, Windsor, R, Michel, Gisela, Frey, E, Mulder, R, van der Pal, J, Levitt, G, Skinner, Rod, Kremer, C, Brown, C, Bardi, E, Windsor, R, Michel, Gisela, and Frey, E

Abstract

Evidence-based clinical practice guidelines are essential to ensure that childhood cancer survivors at risk of chronic health conditions receive effective long-term follow-up (LTFU) care. However, adult survivors of childhood cancer are not always engaged in recommended health promotion and followup practices, as many centres do not have a formal transition programme that prepares survivors and their families for successful transfer from child-centred to adult oriented healthcare. The need for a specific pan-European guideline for the transition of care for childhood cancer survivors has been recognized. The first step is to define the concept of transition of care for survivors of childhood cancer based on existing evidence., + ID der Publikation: unilu_6269 + Sprache: Englisch + Letzte Aktualisierung: 2024-09-17 12:02:13

Published
2016

36. Effect of temperature on the formation of volatile by-products in brewing by immobilized cells

Author

Bardi, E. P., Soupioni, M., Koutinas, A. A., and Kanellaki, M.

Abstract

The formation of acetaldehyde, ethyl acetate, propanol-1, isobutanol, amyl alcohols and methanol in repeated batch fermentations and continuous fermentations of wort, performed by a cryotolerant and alcohol resistant strain of Saccharomyces cerevisiae species, immobilized on delignified cellulosic (D.C.) material and gluten pellets was studied mainly at low temperatures. It was found that the fine and fruity aroma of beers obtained at lower temperatures may be attributed mainly to increase of % ethyl acetate on total volatiles determined and to decrease of amyl alcohols. D.C. material resulted to lower contents of higher alcohols in batch and continuous brewing as compared with gluten and free cells principally at low temperatures. Amyl alcohols and other higher alcohols were reduced in all cases (immobilized and free cells) as the temperature was decreased. Same change of amyl alcohols and other higher alcohols is reported in the case of gluten pellets as the temperature was reduced. However, their contents are higher than those of free cells. In general, comparing the contents of ethyl acetate from continuous and batch process, continuous resulted to higher values. In all cases, the flavor was remained stable for the long period of ten months storage.

Published
1996
Full Text
View/download PDF

38. Preliminary study on hematological values of two endangered turtle species: Indotestudo travancorica and Batagur kachuga.

Author

Bardi, E., Lubian, E., Whitaker, N., and Romussi, S.

Subjects
*ENDANGERED species, *TURTLES, *WILDLIFE conservation
Abstract

The Indian subcontinent is incredibly rich in biodiversity and is home to many species of herpetological and conservation interest. The aim of this study was to provide a first assessment of hematological values in Travancore tortoise (Indotestudo travancorica) and red-crowned roofed turtle (Batagur kachuga), two endangered species on which medical literature is still lacking. Between May and June 2017, 19 healthy specimens of I. travancorica and 17 of B. kachuga were sampled. Both populations were housed by the Madras Crocodile Bank Trust - Centre for Herpetology (Tamil Nadu, India). For each animal, physical examination and fecal analysis were performed. Blood samples (0.5 mL) were obtained from the dorsal coccygeal vein, stored in a lithium-heparin test tube (Bielli et al., 2015) at 10°C (50°F) and processed within three hours. Regarding I. travancorica, from each sample was performed a complete red and white blood cell count (RBC and WBC) with the Natt & Herrik method using a Neubauer chamber, and hematocrit values were assessed using microcapillaries (Nardini et al., 2013). Mean Corpuscular Volume (MCV) was calculated from PCV and RBC. Regarding B. kachuga, complete RBC and WBC count with the same method was performed. Due to the insufficient numerosity of both populations, only descriptive statistic was applied (Friedrichs et al., 2012) (Table 1). Obtained values were compared with known references of species with similar ecological and biological characteristics with results consistent with those of Geochelone elegans (Klaphake et al., 2018) and Mauremys sinensis (Chung et al., 2009). This is the first study on hematological values of I. travancorica and B. kachuga. Further studies will be necessary to assess actual reference values and to investigate other parameters such as WBC differential and erythrocytic [ABSTRACT FROM AUTHOR]

Published
2018

41. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Liv Andrés-Jensen, Andishe Attarbaschi, Edit Bardi, Shlomit Barzilai-Birenboim, Deepa Bhojwani, Melanie M Hagleitner, Christina Halsey, Arja Harila-Saari, Raphaele R L van Litsenburg, Melissa M Hudson, Sima Jeha, Motohiro Kato, Leontien Kremer, Wojciech Mlynarski, Anja Möricke, Rob Pieters, Caroline Piette, Elizabeth Raetz, Leila Ronceray, Claudia Toro, Maria Grazia Valsecchi, Lynda M Vrooman, Sigal Weinreb, Naomi Winick, Kjeld Schmiegelow, Madeline R Adams, Liv Andres-Jensen, Katja Baust, Tineke Boesten, Gabriele Calaminus, Rachel Conyers, Anne-Sophie Darlington, Maëlle de Ville, Gabriele Escherich, Melanie Hagleitner, Jen-Yin Hou, Ting-Huan Huang, Melissa Hudson, Meriel Jenney, Maryna Krawczuk-Rybak, Leontine Kremer, Melchior Lautem, Hse-Che Liu, Elixabet Lopez Lopez, Marion Mateos, Katarzyna Muszynska-Roslan, Riitta Niinimaki, Toby Trahair, Inge van der Sluis, Raphaële van Litsenburg, Lynda Vrooman, Andreas Wiener, Michihiro Yano, Ting-Chi Yeh, Ester Zapotocka, Andres-Jensen, L, Attarbaschi, A, Bardi, E, Barzilai-Birenboim, S, Bhojwani, D, Hagleitner, M, Halsey, C, Harila-Saari, A, van Litsenburg, R, Hudson, M, Jeha, S, Kato, M, Kremer, L, Mlynarski, W, Moricke, A, Pieters, R, Piette, C, Raetz, E, Ronceray, L, Toro, C, Valsecchi, M, Vrooman, L, Weinreb, S, Winick, N, and Schmiegelow, K

Subjects
medicine.medical_specialty, Activities of daily living, MEDLINE, Antineoplastic Agents, Blindness, Antineoplastic Agent, 03 medical and health sciences, 0302 clinical medicine, Refractory, Physicians, Medicine, Humans, Acute lymphocytic leukaemia, Renal Insufficiency, Intensive care medicine, Child, Hearing Loss, Hearing Lo, Severe toxicity, MED/01 - STATISTICA MEDICA, business.industry, Cancer, Hematology, Hematologic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Hematologic Diseases, Progression-Free Survival, Blindne, Clinical trial, Transplantation, Physician, 030220 oncology & carcinogenesis, business, Human, 030215 immunology
Abstract

5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.

Published
2021

42. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Author

Roderick Skinner, Riccardo Haupt, Gisela Michel, Katie Rizvi, Andrea Biondi, Monica Terenziani, Helena J.H. van der Pal, Gabriele Calaminus, participants in PanCare, Michael M. Hawkins, Julianne Byrne, J. D. Beck, Stanislaw Garwicz, Martin Schrappe, Lars Hjorth, Meriel Jenney, Gregory H. Reaman, John J. Spinetta, Edit Bardi, Kevin C. Oeffinger, Eva Frey, Herwig Lackner, Leontien C. M. Kremer, Gerlind Bode, Jaap den Hartogh, Melissa M. Hudson, Claudia E. Kuehni, Momcilo Jankovic, Florent de Vathaire, Gill Levitt, Maria Grazia Valsecchi, Desiree Grabow, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, APH - Quality of Care, Paediatric Oncology, ARD - Amsterdam Reproduction and Development, and CCA - Cancer Treatment and Quality of Life

Subjects
Adult, Male, 0301 basic medicine, Quality of life, medicine.medical_specialty, Adolescent, Statement (logic), education, Childhood cancer, Declaration, Childhood cure, Health informatics, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Cancer Survivors, Neoplasms, medicine, Humans, Childhood care, Survivors, Child, business.industry, Oncology (nursing), Public health, Cancer, medicine.disease, Oncology nursing, 030104 developmental biology, Oncology, Health, 030220 oncology & carcinogenesis, Family medicine, Female, business
Abstract

Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).

Published
2018

44. Sensorless model-based tension control for a cable-driven exosuit.

Author

Bardi E, Esser A, Wolf P, Gandolla M, Ambrosini E, Pedrocchi A, and Riener R

Abstract

Cable-driven exosuits have the potential to support individuals with motor disabilities across the continuum of care. When supporting a limb with a cable, force sensors are often used to measure tension. However, force sensors add cost, complexity, and distal components. This paper presents a design and control approach to remove the force sensor from an upper limb cable-driven exosuit. A mechanical design for the exosuit was developed to maximize passive transparency. Then, a data-driven friction identification was conducted on a mannequin test bench to design a model-based tension controller. Seventeen healthy participants raised and lowered their right arms to evaluate tension tracking, movement quality, and muscular effort. Questionnaires on discomfort, physical exertion, and fatigue were collected. The proposed strategy allowed tracking the desired assistive torque with a root mean square error of 0.71 Nm (18%) at 50% gravity support. During the raising phase, the electromyography signals of the anterior deltoid, trapezius, and pectoralis major were reduced on average compared to the no-suit condition by 30, 38, and 38%, respectively. The posterior deltoid activity was increased by 32% during lowering. Position tracking was not significantly altered, whereas movement smoothness significantly decreased. This work demonstrates the feasibility and effectiveness of removing the force sensor from a cable-driven exosuit. A significant increase in discomfort in the lower neck and right shoulder indicated that the ergonomics of the suit could be improved. Overall this work paves the way toward simpler and more affordable exosuits., Competing Interests: M. Gandolla and A. Pedrocchi hold shares of AGADE srl and AllyArm srl., (© The Author(s) 2024.)

Published
2024
Full Text
View/download PDF

45. Cerebral Amyloid-β Deposition, Axial Features, and Cognitive Alterations in Patients with Parkinson's Disease Treated with Bilateral STN-DBS: A Long-Term Cohort Study.

Author

Cavallieri F, Fraternali A, Arnone A, Campanini I, Marti A, Gessani A, Fioravanti V, Molinari MA, Di Rauso G, Antonelli F, Rispoli V, Feletti A, Stanzani R, Damiano B, Scaltriti S, Cavazzuti L, Bardi E, Corni MG, Cavalleri F, Biagini G, Pavesi G, Lusuardi M, Budriesi C, Merlo A, Versari A, and Valzania F

Abstract

Objectives: Our aim was to evaluate the possible long-term cerebral deposition of amyloid-β in patients with PD treated with subthalamic nucleus deep brain stimulation (STN-DBS) and its possible influence on axial and cognitive variables. Methods: Consecutive PD patients treated with bilateral STN-DBS with a long-term follow-up were included. The amyloid-β deposition was evaluated postoperatively through an 18F-flutemetamol positron emission tomography (PET) study. Axial symptoms were assessed using a standardized clinical-instrumental approach. The speech was assessed by perceptual and acoustic analysis, while gait was assessed by means of the instrumented Timed Up and Go test (iTUG). Motor severity was evaluated by applying the UPDRS part III score and subscores, while cognitive functions were assessed through a complete neuropsychological assessment. Different stimulation and drug conditions were assessed: on-stimulation/off-medication, off-stimulation/off-medication, and on-stimulation/on-medication conditions (single- and dual-task). Results: In total, 19 PD patients (male: 11; age: 63.52 years; on-stimulation/on-medication UPDRS-III: 17.05) with a five-year postoperative follow-up were included. The amyloid-β deposition was found in 21% of patients (4/19) with a prevalent involvement of prefrontal, limbic, and parietal areas. Compared with patients without amyloid-β deposition, PD patients with positive 18F-flutemetamol in the PET study showed a higher preoperative UPDRS-I ( p = 0.037) score. Conclusions: Our results suggest that in the long term, after STN-DBS, a significant percentage of PD patients may present brain amyloid-β deposition. However, larger samples are needed to evaluate the possible role of amyloid-β deposition in the development of axial and cognitive alterations after surgery.

Published
2024
Full Text
View/download PDF

46. Radiation Doses Received by Major Organs at Risk in Children and Young Adolescents Treated for Cancer with External Beam Radiation Therapy: A Large-scale Study from 12 European Countries.

Author

Diallo I, Allodji RS, Veres C, Bolle S, Llanas D, Ezzouhri S, Zrafi W, Debiche G, Souchard V, Fauchery R, Haddy N, Journy N, Demoor-Goldschmidt C, Winter DL, Hjorth L, Wiebe T, Haupt R, Robert C, Kremer L, Bardi E, Sacerdote C, Terenziani M, Kuehni CE, Schindera C, Skinner R, Winther JF, Lähteenmäki P, Byrn J, Jakab Z, Cardis E, Pasqual E, Tapio S, Baatout S, Atkinson M, Benotmane MA, Sugden E, Zaletel LZ, Ronckers C, Reulen RC, Hawkins MM, and de Vathaire F

Subjects
Humans, Child, Adolescent, Europe, Child, Preschool, Male, Female, Infant, Cancer Survivors statistics & numerical data, Whole-Body Irradiation adverse effects, Whole-Body Irradiation methods, Phantoms, Imaging, Radiotherapy Planning, Computer-Assisted methods, Organs at Risk radiation effects, Neoplasms radiotherapy, Radiotherapy Dosage
Abstract

Purpose: Childhood cancer survivors, in particular those treated with radiation therapy, are at high risk of long-term iatrogenic events. The prediction of risk of such events is mainly based on the knowledge of the radiation dose received to healthy organs and tissues during treatment of childhood cancer diagnosed decades ago. We aimed to set up a standardized organ dose table to help former patients and clinicians in charge of long-term follow-up clinics., Methods and Materials: We performed whole body dosimetric reconstruction for 2646 patients from 12 European countries treated between 1941 and 2006 (median, 1976). Most plannings were 2- or 3-dimensional. A total of 46% of patients were treated using Cobalt 60, and 41%, using a linear accelerator. The median prescribed dose was 27.2 Gy (IQ1-IQ3, 17.6-40.0 Gy). A patient-specific voxel-based anthropomorphic phantom with more than 200 anatomic structures or substructures delineated as a surrogate of each subject's anatomy was used. The radiation therapy was simulated with a treatment planning system based on available treatment information. The radiation dose received by any organ of the body was estimated by extending the treatment planning system dose calculation to the whole body, by type and localization of childhood cancer., Results: The integral dose and normal tissue doses to most of the 23 considered organs increased between the 1950s and 1970s and decreased or plateaued thereafter. Whatever the organ considered, the type of childhood cancer explained most of the variability in organ dose. The country of treatment explained only a small part of the variability., Conclusions: The detailed dose estimates provide very useful information for former patients or clinicians who have only limited knowledge about radiation therapy protocols or techniques, but who know the type and site of childhood cancer, sex, age, and year of treatment. This will allow better prediction of the long-term risk of iatrogenic events and better referral to long-term follow-up clinics., (Copyright © 2024. Published by Elsevier Inc.)

Published
2024
Full Text
View/download PDF

47. Assessment of HL7 FHIR Interoperability Between EHR Systems and the Survivorship Passport v2.0 Platform to Generate Treatment Summaries for Childhood Cancer Survivors in Six Clinics: Preliminary Testing Results.

Author

Saraceno D, Chronaki C, Cangioli G, Filbert AL, Muraca M, Berti A, Rielli R, Thomopulos N, Knoerr L, Walz D, Neumann A, Beccaria A, Aulicino A, Nicolas B, Cavalca G, Uyttebroeck A, van Helvoirt M, Brié T, Vanden Meersch E, Ladenstein R, Bardi E, Schreier G, Beyer S, Müllner-Rieder M, Tormo Alcañiz MT, Cervero Beltran L, Rascon J, Kapitančukė M, Trinkūnas J, Stukaitė-Ruibienė E, Ragauskas P, Ciesiūnienė A, Haupt R, and Grabow D

Subjects
Humans, Child, Europe, Health Level Seven, Neoplasms therapy, Health Information Interoperability, Electronic Health Records, Cancer Survivors
Abstract

The Survivorship Passport (SurPass) for childhood cancer survivors provides a personalized treatment summary together with a care plan for long-term screening of possible late effects. HL7 FHIR connectivity of Electronic Health Record (EHR) systems with the SurPass has been proposed to reduce the burden of collecting and organizing the relevant information. We present the results of testing and validation efforts conducted across six clinics in Austria, Belgium, Germany, Italy, Lithuania, and Spain. We also discuss ways in which this experience can be used to reduce efforts for the SurPass integration in other clinics across Europe.

Published
2024
Full Text
View/download PDF

48. Barriers, facilitators, and other factors associated with health behaviors in childhood, adolescent, and young adult cancer survivors: A systematic review.

Author

de Beijer IAE, Bouwman E, Mulder RL, Steensma P, Brown MC, Araújo-Soares V, Balcerek M, Bardi E, Falck Winther J, Frederiksen LE, van Gorp M, Oberti S, van Kalsbeek RJ, Kepak T, Kepakova K, Gsell H, Kienesberger A, van Litsenburg R, Mader L, Michel G, Muraca M, van den Oever SR, van der Pal HJH, Roser K, Skinner R, Stolman I, Uyttebroeck A, Kremer LCM, Loonen J, van Dalen EC, and Pluijm SMF

Subjects
Adolescent, Adult, Child, Female, Humans, Male, Middle Aged, Young Adult, Alcohol Drinking epidemiology, Diet, Neoplasms psychology, Neoplasms epidemiology, Smoking epidemiology, Smoking adverse effects, Cancer Survivors psychology, Exercise, Health Behavior
Abstract

Background: Healthy behaviors are paramount in preventing long-term adverse health outcomes in childhood, adolescent, and young adult (CAYA) cancer survivors. We systematically reviewed and synthesized existing literature on barriers, facilitators, and other factors associated with health behaviors in this population., Methods: MEDLINE and PsycInfo were searched for qualitative and quantitative studies including survivors aged 16-50 years at study, a cancer diagnosis ≤25 years and ≥2 years post diagnosis. Health behaviors included physical activity, smoking, diet, alcohol consumption, sun exposure, and a combination of these behaviors (defined as health behaviors in general)., Results: Barriers, facilitators, and other factors reported in ≥2 two studies were considered relevant. Out of 4529 studies, 27 were included (n = 31,905 participants). Physical activity was the most frequently examined behavior (n = 12 studies), followed by smoking (n = 7), diet (n = 7), alcohol (n = 4), sun exposure (n = 4), and health behavior in general (n = 4). Relevant barriers to physical activity were fatigue, lack of motivation, time constraints, and current smoking. Relevant facilitators were perceived health benefits and motivation. Influence of the social environment and poor mental health were associated with more smoking, while increased energy was associated with less smoking. No relevant barriers and facilitators were identified for diet, alcohol consumption, and sun exposure. Barriers to healthy behavior in general were unmet information needs and time constraints whereas lifestyle advice, information, and discussions with a healthcare professional facilitated healthy behavior in general. Concerning other factors, women were more likely to be physically inactive, but less likely to drink alcohol and more likely to comply with sun protection recommendations than men. Higher education was associated with more physical activity, and lower education with more smoking., Conclusion: This knowledge can be used as a starting point to develop health behavior interventions, inform lifestyle coaches, and increase awareness among healthcare providers regarding which survivors are most at risk of unhealthy behaviors., (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

49. Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study.

Author

van den Oever SR, de Beijer IAE, Kremer LCM, Alfes M, Balaguer J, Bardi E, Nieto AC, Cangioli G, Charalambous E, Chronaki C, Costa T, Degelsegger A, Düster V, Filbert AL, Grabow D, Gredinger G, Gsell H, Haupt R, van Helvoirt M, Ladenstein R, Langer T, Laschkolnig A, Muraca M, Rascon J, Schreier G, Tomasikova Z, Tormo MT, Trinkunas J, Trollip J, Trunner K, Uyttebroeck A, van der Pal HJH, and Pluijm SMF

Subjects
Humans, Europe, Surveys and Questionnaires, Male, Female, Quality of Life, Neoplasms therapy, Cancer Survivors psychology, Survivorship
Abstract

Purpose: Long-term follow-up (LTFU) care for childhood cancer survivors (CCSs) is essential to improve and maintain their quality of life. The Survivorship Passport (SurPass) is a digital tool which can aid in the delivery of adequate LTFU care. During the European PanCareSurPass (PCSP) project, the SurPass v2.0 will be implemented and evaluated at six LTFU care clinics in Austria, Belgium, Germany, Italy, Lithuania and Spain. We aimed to identify barriers and facilitators to the implementation of the SurPass v2.0 with regard to the care process as well as ethical, legal, social and economical aspects., Methods: An online, semi-structured survey was distributed to 75 stakeholders (LTFU care providers, LTFU care program managers and CCSs) affiliated with one of the six centres. Barriers and facilitators identified in four centres or more were defined as main contextual factors influencing implementation of SurPass v2.0., Results: Fifty-four barriers and 50 facilitators were identified. Among the main barriers were a lack of time and (financial) resources, gaps in knowledge concerning ethical and legal issues and a potential increase in health-related anxiety in CCSs upon receiving a SurPass. Main facilitators included institutions' access to electronic medical records, as well as previous experience with SurPass or similar tools., Conclusions: We provided an overview of contextual factors that may influence SurPass implementation. Solutions should be found to overcome barriers and ensure effective implementation of SurPass v2.0 into routine clinical care., Implications for Cancer Survivors: These findings will be used to inform on an implementation strategy tailored for the six centres., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

50. IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.

Author

de Beijer IAE, van den Oever SR, Charalambous E, Cangioli G, Balaguer J, Bardi E, Alfes M, Cañete Nieto A, Correcher M, Pinto da Costa T, Degelsegger-Márquez A, Düster V, Filbert AL, Grabow D, Gredinger G, Gsell H, Haupt R, van Helvoirt M, Ladenstein R, Langer T, Laschkolnig A, Muraca M, Pluijm SMF, Rascon J, Schreier G, Tomášikova Z, Trauner F, Trinkūnas J, Trunner K, Uyttebroeck A, Kremer LCM, van der Pal HJH, and Chronaki C

Subjects
Humans, Europe, Surveys and Questionnaires, Electronic Health Records, Cancer Survivors, Computer Security, Survivorship, Telemedicine methods
Abstract

Background: To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project, the semiautomated and interoperable SurPass (version 2.0) will be optimized, implemented, and evaluated at 6 LTFU care centers representing 6 European countries and 3 distinct health system scenarios: (1) national electronic health information systems (EHISs) in Austria and Lithuania, (2) regional or local EHISs in Italy and Spain, and (3) cancer registries or hospital-based EHISs in Belgium and Germany., Objective: We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity., Methods: IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs., Results: In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios., Conclusions: This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs., (©Ismay A E de Beijer, Selina R van den Oever, Eliana Charalambous, Giorgio Cangioli, Julia Balaguer, Edit Bardi, Marie Alfes, Adela Cañete Nieto, Marisa Correcher, Tiago Pinto da Costa, Alexander Degelsegger-Márquez, Vanessa Düster, Anna-Liesa Filbert, Desiree Grabow, Gerald Gredinger, Hannah Gsell, Riccardo Haupt, Maria van Helvoirt, Ruth Ladenstein, Thorsten Langer, Anja Laschkolnig, Monica Muraca, Saskia M F Pluijm, Jelena Rascon, Günter Schreier, Zuzana Tomášikova, Florian Trauner, Justas Trinkūnas, Kathrin Trunner, Anne Uyttebroeck, Leontien C M Kremer, Helena J H van der Pal, Catherine Chronaki, PanCareSurPass Consortium. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 02.05.2024.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results